5. Conclusions
bleeding, dyspnea
BLEEDING
This study showed that the prevalence of dyspnea among patients treated with ticagrelor was higher than that of those using clopidogrel. However, most of the patients in both groups experienced mild dyspnea. Interestingly, this study demonstrated that ticagrelor can induce more new-onset dyspnea in patients than clopidogrel. Although the patients who used clopidogrel had better medication adherence than the ones taking ticagrelor, the prevalence of MACE was less with ticagrelor. There were no significant differences between clopidogrel and ticagrelor regarding the bleeding risk.